CYP2D6 phenotype prediction from genotype: which system is the best?

Clin Pharmacol Ther. 2008 Feb;83(2):225-7. doi: 10.1038/sj.clpt.6100455.

Abstract

Genotyping of the polymorphic cytochrome P450 (CYP) 2D6 gene is used increasingly in clinical practice. Several psychiatric hospitals already use CYP2D6 testing before treating a patient with antidepressant or antipsychotic drug therapy. In other fields of drug therapy, such as for breast cancer, CYP2D6 status has been reported to be an independent predictor for the outcome with tamoxifen. Thus, a more favorable tamoxifen treatment seems to be feasible through a priori genetic assessment of CYP2D6.

Publication types

  • Comment

MeSH terms

  • Antidepressive Agents / metabolism
  • Antidepressive Agents / therapeutic use
  • Antineoplastic Agents, Hormonal / metabolism
  • Antineoplastic Agents, Hormonal / therapeutic use
  • Antipsychotic Agents / metabolism
  • Antipsychotic Agents / therapeutic use
  • Black People / genetics
  • Cluster Analysis
  • Cytochrome P-450 CYP2D6 / genetics*
  • Cytochrome P-450 CYP2D6 / metabolism*
  • Dextromethorphan / metabolism
  • Dextromethorphan / urine
  • Gene Frequency
  • Genetic Testing
  • Genotype
  • Humans
  • Linear Models
  • Models, Genetic*
  • Patient Selection
  • Pharmacogenetics*
  • Phenotype
  • Polymorphism, Genetic*
  • Reproducibility of Results
  • Substrate Specificity
  • Tamoxifen / metabolism
  • Tamoxifen / therapeutic use
  • Treatment Outcome
  • White People / genetics

Substances

  • Antidepressive Agents
  • Antineoplastic Agents, Hormonal
  • Antipsychotic Agents
  • Tamoxifen
  • Dextromethorphan
  • Cytochrome P-450 CYP2D6